Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial

Estrella Immunopharma, Inc.

Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.
Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.
Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.
Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.